NNNN
Anbio Biotechnology Class A Ordinary Shares
NASDAQ: NNNN · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$27.43
-1.37% today
Updated 2026-04-29
Market cap
$1.20B
P/E ratio
182.87
P/S ratio
139.23x
EPS (TTM)
$0.15
Dividend yield
—
52W range
$6 – $56
Volume
0.0M
Anbio Biotechnology Class A Ordinary Shares (NNNN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $4.43M | $23.54M | $6.71M | $8.19M | $8.65M |
| Revenue growth (YoY) | — | +431.7% | -71.5% | +21.9% | +5.6% |
| Cost of revenue | $1.89M | $10.98M | $3.35M | $2.30M | $1.10M |
| Gross profit | $2.54M | $12.56M | $3.36M | $5.89M | $7.54M |
| Gross margin | 57.4% | 53.4% | 50.1% | 71.9% | 87.2% |
| R&D | $0.00 | $200000.00 | $134700.00 | $454227.00 | $201305.00 |
| SG&A | $86095.00 | $2.17M | $1.27M | $3.44M | $1.57M |
| Operating income | $2.46M | $10.20M | $1.96M | $2.00M | $5.77M |
| Operating margin | 55.5% | 43.3% | 29.2% | 24.4% | 66.7% |
| EBITDA | $2.54M | $10.03M | $2.27M | $2.57M | $5.77M |
| EBITDA margin | 57.3% | 42.6% | 33.8% | 31.4% | 66.7% |
| EBIT | $2.46M | $10.02M | $2.25M | $2.00M | — |
| Interest expense | $0.00 | $7999.00 | $0.00 | $0.00 | — |
| Income tax | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $2.54M | $10.01M | $2.25M | $2.37M | $6.40M |
| Net income growth (YoY) | — | +294.8% | -77.5% | +5.3% | +169.9% |
| Profit margin | 57.3% | 42.5% | 33.6% | 29.0% | 74.1% |